Pitcairn Co. Sells 6,278 Shares of Abbott Laboratories $ABT

Pitcairn Co. lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 20.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,373 shares of the healthcare product maker’s stock after selling 6,278 shares during the period. Pitcairn Co.’s holdings in Abbott Laboratories were worth $3,265,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the third quarter worth $31,000. Anfield Capital Management LLC lifted its stake in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $33,000. 75.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on ABT. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Leerink Partners cut their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Citigroup cut their price objective on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Stock Down 1.9%

Abbott Laboratories stock opened at $110.97 on Friday. The company has a market capitalization of $192.83 billion, a PE ratio of 29.83, a PEG ratio of 1.80 and a beta of 0.74. The firm’s fifty day moving average is $116.39 and its 200 day moving average is $124.82. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.15.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insiders Place Their Bets

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.